IQV vs NTRA
IQVIA and Natera, Inc., both Healthcare
Natera, Inc. is the larger company at $37B against $28B. Over the past year NTRA returned +121% against +37% for IQV. The RyuScore puts IQV ahead, 70 against 18 out of 100.
| Figure | IQV | NTRA |
|---|---|---|
| Last close | $260 | $401 |
| Market cap | $28B | $37B |
| Trailing P/Elower is cheaper for the same earnings, not automatically better | 32.3 | n/a |
| 1-year return | +37% | +121% |
| 5-year return | +1.7% | +234% |
| RyuScoresector-relative, 1–10 | 70/100 | 18/100 |
Figures from SEC filings and end-of-day closes. Highlighting marks the higher or lower number, which is not the same as the better investment, a low P/E can be a warning and a high one can be deserved.
IQVIA
Revenue of $4.2B in Q1 2026, net income $274M. Its largest reported line is Research And Development Solutions, 56% of the disclosed total.
Natera, Inc.
Revenue of $753M in Q2 2026, net income null. Its largest reported line is United States, 98% of the disclosed total.
Open these two in the interactive comparison to add more names, change the period or see the correlation.